Refractory Epilepsy Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Refractory Epilepsy Market is segmented By Drug Class (First-Generation, Second-Generation, Third-Generation), By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Refractory Epilepsy Market Size
Market Size in USD
CAGR4.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 4.2% |
| Market Concentration | High |
| Major Players | Pfizer, Novartis, Abbott, Neurelis Inc, GSK Plc |
please let us know !
Refractory Epilepsy Market Analysis
The Global Refractory Epilepsy Market is estimated to be valued at USD 1.2 Bn in 2024 and is expected to reach USD 3.1 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031. New treatments in the pipeline and increasing prevalence of drug-resistant epilepsy is contributing to the growth of this market.
The refractory epilepsy market iswitnessing positive trend with increasing research and development activities in this field. Many pharmaceutical companies are actively working on developing novel treatment options to target the underlying cause of epilepsy. Additionally, the growing geriatric population worldwide who are more prone to develop drug-resistant epilepsy will further drive the demand in this market during the forecast period.